B+
Bull case
20%
Probability
Target price
$0.90
+45.2% vs current
RKDA
Arcadia BiosciencesBNasdaq / Food Beverage & Tobacco
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.65
+4.8% vs current
B-
Bear case
35%
Probability
Target price
$0.30
-51.6% vs current
AI sentiment snapshot
Latest data as of 2026-07-14
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+32.4
Score
AI commentary
News tone is mixed: company-reported volume and SG&A metrics were constructive, but revenue declined and the net loss was substantial. Coverage is thin and mainly earnings-wire based; analyst reaction, options, short interest, employee sentiment, and social sentiment are unavailable, so this remains a low-conviction monitoring view.
RankAlpha Sentiment Codex - 2026-07-14
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-07-14catalystNear-term liquidity support from option exercisesHigh impact
The Q1 filing reported approximately $2.1 million of gross proceeds from exercises of previously outstanding preferred investment options, which may reduce immediate funding pressure but does not establish durable profitability [#SEC-8K-2026-05-14].
2026-09-30eventFall product launch and distribution testHigh impact
Management expects a new product to reach shelves at many of its largest customers in the fall, creating the clearest dated operating test for incremental distribution and revenue [#SEC-8K-2026-05-14].
2026-12-31catalystZola growth must translate into a cleaner P&LHigh impact
Zola volumes rose 18% year over year and SG&A declined, but Q1 revenue fell 8% to $1.1 million and net loss was $4.4 million. A durable thesis requires continued volume growth and cost control to produce improving operating results [#SEC-8K-2026-05-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-14 • Updated nightlySource: Internal modelMethodology